Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 – December 2019
Author
Merdrignac, Lore
El Belghiti, Fatima Aït
Pandolfi, Elisabetta
Acosta, Lesly
Fabiánová, Kateřina
Habington, Adele
García Cenoz, Manuel
Bøås, Håkon
Toubiana, Julie
Tozzi, Alberto E.
Jordan, Iolanda
Zavadilová, Jana
O'Sullivan, Niam
Navascués, Ana
Flem, Elmira
Croci, Ilena
Jané, Mireia
Křížová, Pavla
Cotter, Suzanne
Fernandino, Leticia
Bekkevold, Terese
Bacci, Sabrina
Kramarz, Piotr
Kissling, Esther
Savulescu, Camelia
Renacoq Group
The PERTINENT Group
Publication date
2024ISSN
0264-410X
Abstract
Background: Monitoring effectiveness of pertussis vaccines is necessary to adapt vaccination strategies. PERTINENT, Pertussis in Infants European Network, is an active sentinel surveillance system implemented in 35 hospitals across six EU/EEA countries. We aim to measure pertussis vaccines effectiveness (VE) by dose against hospitalisation in infants aged <1 year. Methods: From December 2015 to December 2019, participating hospitals recruited all infants with pertussis-like symptoms. Cases were vaccine-eligible infants testing positive for Bordetella pertussis by PCR or culture; controls were those testing negative to all Bordetella spp. For each vaccine dose, we defined an infant as vaccinated if she/he received the corresponding dose >14 days before symptoms. Unvaccinated were those who did not receive any dose. We calculated (one-stage model) pooled VE as 100*(1-odds ratio of vaccination) adjusted for country, onset date (in 3-month categories) and age-group (when sample allowed it). Results: Of 1,393 infants eligible for vaccination, we included 259 cases and 746 controls. Median age was 16 weeks for cases and 19 weeks for controls (p < 0.001). Median birth weight and gestational age were 3,235 g and week 39 for cases, 3,113 g and week 39 for controls. Among cases, 119 (46 %) were vaccinated: 74 with one dose, 37 two doses, 8 three doses. Among controls, 469 (63 %) were vaccinated: 233 with one dose, 206 two doses, 30 three doses. Adjusted VE after at least one dose was 59 % (95 %CI: 36–73). Adjusted VE was 48 % (95 %CI: 5–71) for dose one (416 eligible infants) and 76 % (95 %CI: 43–90) for dose two (258 eligible infants). Only 42 infants were eligible for the third dose. Conclusions: Our results suggest moderate one-dose and two-dose VE in infants. Larger sample size would allow more precise estimates for dose one, two and three.
Document Type
Article
Document version
Published version
Language
English
Subject (CDU)
61 - Medical sciences
Keywords
Tos ferina
Vacuna contra la tos ferina
Efectivitat de la vacuna
Vigilància hospitalària
Tos ferina
Vacuna contra la tos ferina
Eficacia de la vacuna
Vigilancia hospitalaria
Tos ferina
Vacuna contra la tos ferina
Efectivitat de la vacuna
Vigilància hospitalària
Pertussis
Whooping cough
Pertussis vaccine
Vaccine effectiveness
Hospital surveillance
Pages
9
Publisher
Elsevier
Collection
42;9
Is part of
Vaccine
Citation
Merdrignac, Lore El Belghiti, Fatima Aït Pandolfi, Elisabetta [et al.]. Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 – December 2019. Vaccine, 2024, 42(9), p. 2370-2379. Disponible en: <https://www.sciencedirect.com/science/article/pii/S0264410X2400272X?via%3Dihub>. Fecha de acceso: 5 abr. 2024. DOI: 10.1016/j.vaccine.2024.02.090
This item appears in the following Collection(s)
- Ciències de la Salut [725]
Rights
© 2024 The Author(s). Published by Elsevier Ltd.
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/